Lactobacillus rhamnosus 35 as Next Generation Probiotics
Lactobacillus rhamnosus 35, also known as Lactobacillus casei rhamnosus 35, is an aerotolerant, homofermentative bacterium originally isolated from the gut flora of a healthy infant. The bacterium has been successfully used as a probiotic in the drug and food industry for improving gastrointestinal diseases. As a pioneer in the development of next-generation probiotics, Creative Biolabs is committed to providing customers with a full range of next-generation probiotics development services at high quality and low cost. Our services include identification and isolation of L. rhamnosus 35, safety test for probiotics, host-microbe interaction test, and cGMP manufacturing.
Introduction of L. rhamnosus 35
L. rhamnosus 35, also known as Lactobacillus casei rhamnosus 35, is a member of the genus Lactobacillus of ubiquitous anaerobic gram-positive microorganisms. Like other members of the genus Lactobacillus, L. rhamnosus 35 also produces carbon dioxide, ethanol, acetate, and lactic acid from glucose fermentation. This strain was originally isolated from the gut flora of a healthy infant. It has been successfully used as a pharmaceutical probiotic for more than 4 years. Some studies have shown L. rhamnosus 35 can survive and persist in the gastrointestinal tract as well as inhibit the growth and adherence of several pathogens.
Potential of L. rhamnosus 35 Probiotics
In an open randomized pilot study enrolled 20 healthy women of child-bearing age, oral administration of L. rhamnosus 35 with a dose of 2×108 CFU/day can restore or maintain a normal vaginal microbiota in healthy premenopausal women. Besides, L. rhamnosus 35 has a preventive or curative impact on a range of vaginal disorders such as bacterial vaginosis or vulvovaginal candidiasis without adverse effects. However, there still needs large-scale clinical studies to further verify the safety and efficacy of L. rhamnosus 35 probiotics in the treatment of vaginal disorders.
-
Gastrointestinal and Other Infectious Diseases
L. rhamnosus 35 has been demonstrated as probiotics for prevention and treatment of a broad number of gastrointestinal and other infectious diseases. A in vitro assay showed that L. rhamnosus 35 inhibited the growth of nine human pathogenic bacteria, including ETEC, EPEC, K. pneumoniae, Shigella flexneri, Salmonella typhimurium, Enterobacter cloacae, Pseudomonas aeruginosa, Enterococcus faecalis, and Clostridium difficile. However, no bactericidal activity was detected in this in vitro assay.
In a double-blind placebo-controlled, randomized study enrolled 45 children under 10 years old with chronic constipation, L. rhamnosus 35 can effectively relieve the symptom of chronic constipation. Although there is no significant difference between MgO and L. rhamnosus 35 in the treatment of chronic constipation, L. rhamnosus 35 supplementation reduces the occurrence of abdominal pain.
As a company specializing in the identification and production of next-generation probiotics, Creative Biolabs effectively supports a full range of probiotics identification, production, and safety test services. Our services help reduce the cost of failure and increase the chance of success for researchers and probiotics companies. If you are interested in our services, please feel free to contact us to discuss your project. We will become your reliable partner for next-generation probiotics development.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
